Skip to main content
. 2018 Aug 23;36(29):2926–2934. doi: 10.1200/JCO.2018.77.7250

Fig A2.

Fig A2.

Cumulative incidence rate of relapse by site for Capizzi-style escalating intravenous methotrexate (C-MTX) and high-dose methotrexate (HDMTX) randomly assigned cohorts. (A) Isolated bone marrow relapse. (B) Isolated CNS relapse. (C) Combined bone marrow and CNS relapse.